October 18th 2024
New research better defines the link between cardiovascular disease risk and prevalence of ED per serum ceramide levels.
Urethral lift found safe, efficacious in real-world setting
August 12th 2019A study evaluating outcomes of the prostatic urethral lift (PUL; UroLift System) in clinical practice show that the efficacy and safety documented in the selected group of men enrolled in clinical trials is maintained across the broader spectrum of patients who present for treatment of symptomatic BPH in the real-world setting.
Shock wave therapy: ED cure or unproven treatment?
August 6th 2019Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important unanswered questions, including which patients are ideal candidates and which protocol and devices are best.
Post-prosthesis infection data alter conventional thinking
March 29th 2019"The observations that penile prosthesis surgical infections occurring early are frequently associated with anaerobic bacterial organisms and that these infections overall comprise diverse pathogens including fungal organisms fundamentally alter conventional thinking related to this topic area," writes Arthur L. Burnett, II, MD, MBA.
Data reveal timeline of post-IPP infections
March 29th 2019Isolated anaerobic organisms appear to occur most rapidly on average when infections occur following surgical intervention with an inflatable penile prosthesis (IPP), according to data presented at the 2018 AUA annual meeting in San Francisco.
High paternal age may raise PCa rate
December 12th 2018The public health impact of increasing paternal age requires further investigation, and clinicians should discuss with their patients the potential impact older fathers may have on their children, according to researchers at Stanford University School of Medicine, Stanford, CA.
BPH procedures and med use: Two sides of a coin
November 14th 2018"When analyzing efficacy of minimally invasive/surgical therapies for lower urinary tract symptoms secondary to BPH, we appropriately focus on subjective criteria and objective criteria. While we discuss retreatment rates, we don’t measure failure of therapies by how many men restart LUTS/BPH medications," writes Steven A. Kaplan, MD.